Announcements Trials
Browse Landscape

Phase

Phase 3 14Phase 2 13Phase NA 11Phase 4 11Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 1Pruritus 1Nausea 1Breast Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Aprepitant × Clear all
NCT06931119 2025-04-17

Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

Rabin Medical Center

Phase 1 Not yet recruiting
30 enrolled

Pruritus

NCT00719173 2024-11-04

NRR

UNC Lineberger Comprehensive Cancer Center

Phase 1 Completed
19 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡